2024 highlights include expanded product labeling, key FDA designations and new study publications
Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval
https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-11-6-fourth-quarter-2024-revenue-growth-302391883.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.